• Release date: December 10, 2021
• Expiration date: December 31, 2024
• Estimated time to complete activity: 14 hours
• Jointly provided by Postgraduate Institute for Medicine and CME Science
Course Description
With the recent approval by CMS Medicare for DOTATATE (NETSPOT) PET/CT and the rapid international adoption of targeted Lu-177 based therapies for neuroendocrine and prostate cancers, it is clear that Nuclear Medicine and PET/CT are entering into a new era. New diagnostic and therapeutic agents with remarkable sensitivity and specificity are revolutionizing Nuclear Medicine and Oncology. This course will highlight the latest targeted imaging agents for neuroendocrine and prostate cancers (Ga-68 DOTATATE and Ga-68 PSMA PET/CT) as well as review important core concepts in PET/CT imaging and therapeutic Nuclear Medicine.
This course provides a clinical perspective of PET/CT imaging and the emerging use of Theranostic agents within Nuclear Medicine. A broad perspective on the economic, clinical, and academic aspects of the latest trends in PET/CT imaging and Nuclear Medicine therapy will be presented.
Objectives
• Describe new developments in the merger of diagnostic and therapeutic radioligands for PET/CT imaging and therapy with specific focus on DOTA, PSMA, and PRRT
• Describe the logistics of bringing these new diagnostic and therapeutic technologies to clinical practice
• Identify the key clinical indications for new emerging tracers for Neuroendocrine Tumor and Prostate cancer using somatostatin receptor and PSMA PET/CT imaging
• Review and discuss the standard-of-care clinical application and advanced interpretation of FDG PET/CT
Target Audience
This course is intended for practicing radiologists, nuclear medicine physicians and radiologic nurses, physician assistants, technologists, residents, fellows and others who are interested in the clinical applications of PET and PET/CT.
Faculty
David M. Naeger, MD
• Assistant Professor of Radiology at Stanford University School of Medicine
• Specialties include Medical imaging hardware and software, molecular imaging, protein expression and purification
Don C. Yoo, MD
• Assistant Professor of Radiology at Stanford University School of Medicine
• Specialties include Medical imaging hardware and software, molecular imaging, protein expression and purification
Andrew Quon, MD
• Assistant Professor of Radiology at Stanford University School of Medicine
• Specialties include Medical imaging hardware and software, molecular imaging, protein expression and purification
Course Curriculum
Advanced PET Imaging, Nuclear Medicine, and Therapy: From Diagnostics to Theranostics
Course Curriculum
- Importance of Patient Preparation for PET/CT (Oncology and Cardiac Sarcoidosis) - Don C. Yoo, MD
- Update on Nuclear Medicine for Infection and Inflammation - Don C. Yoo, MD
- Evaluation and Treatment of Benign Thyroid Disease - Andrew Quon, MD
- Nuclear Medicine and Benign Thyroid Disease - Andrew Quon, MD
- Somatostatin Radiotherapy: The New Era of Nuclear Medicine Therapeutics - Andrew Quon, MD
- Challenging and Instructive Abdomen and Pelvis PET/CT Review - Don C. Yoo, MD
- Neuroendocrine Tumor Imaging with DOTA PET/CT - Andrew Quon, MD
- PET/CT of the Four T's and Esophageal Cancer - David M. Naeger, MD
- Prostate Cancer PET Imaging - Andrew Quon, MD
- Incidentals and Artifacts on PET/CT - David M. Naeger, MD
- Comprehensive Approach to Lung Cancer Imaging - David M. Naeger, MD
- When FDG PET is No Good: Situations in Which FDG PET Has Low-Sensitivity - David M. Naeger, MD
- Challenging and Instructive Chest PET/CT Review - Don C. Yoo, MD
- Pulmonary Nodules: CT and PET/CT Assessment - David M. Naeger, MD
- PET/CT in Head and Neck Cancer - Don C. Yoo, MD
- Metastatic Castration-Reistant Prostate Cancer - Andrew Quon, MD
- Back to Basics Nuclear Medicine - Andrew Quon, MD
- Claim Your CME
Pricing
$1,395
Advanced PET Imaging, Nuclear Medicine, and Therapy: From Diagnostics to Theranostics
14 AMA PRA Category 1 Credit(s)™
Closed for enrollment. Please visit our updated course "PET On-Demand 2024"
Refund Policy: Cancellation and refund requests must be made within 24 hours of purchase. Within the first 24 hours you may cancel and be refunded the full amount of the purchase , less a $100.00 administrative fee. After 24 hours no refunds will be allowed.
Please note: If you have applied for CME credit during this period “NO” refunds will be available.
Important Notice Regarding Copyright and Usage
All materials purchased from CME Science are protected by copyright and are for the sole personal use of the purchaser.
Distributing, forwarding, transferring, reproducing, or reselling these educational materials in any way is strictly prohibited and constitutes copyright infringement. This includes, but is not limited to, sharing them with others, posting them online, or incorporating them into other products or services.
Your license to access these materials is non-transferable and applies only to you, the original purchaser.
We reserve the right to terminate or restrict your access to our service, without prior notice, if we find any violation of these terms and conditions.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and CME Science. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 14 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Faculty
The faculty members have nothing to disclose.
Planners and Managers
The PIM planners and managers have nothing to disclose. The CME Science planners and managers have nothing to disclose.
Method of Participation and Request for Credit
During the period December 10, 2021 through December 31, 2024, participants must read the learning objectives and faculty disclosures and study the educational activity.
Media
Internet
Computer System Requirements
Any online accessible device.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.